{"id":46,"date":"2010-02-04T16:06:48","date_gmt":"2010-02-04T16:06:48","guid":{"rendered":"http:\/\/blogs.dickinson.edu\/sciencenews\/?p=46"},"modified":"2010-02-15T22:52:32","modified_gmt":"2010-02-15T22:52:32","slug":"new-drug-shown-to-heal-back-pain-in-3-days","status":"publish","type":"post","link":"https:\/\/blogs.dickinson.edu\/sciencenews\/2010\/02\/04\/new-drug-shown-to-heal-back-pain-in-3-days\/","title":{"rendered":"New Drug Shown to Heal Back Pain in 3 Days"},"content":{"rendered":"

By Johnathan Nieves<\/em><\/p>\n

\"\"<\/a>
Source: Belmar-Fitness <\/figcaption><\/figure>\n

Lower back pain<\/a> is the fifth leading cause for doctor visits in the U.S. and over 85 percent of people suffer at least one bout of lower back pain in their lifetime. SOMA\u00ae, a new drug under development by, Meda Pharmaceuticals, Inc., a Somerset, N.J. based company, has been shown to improve functionality and reduce disability associated with lower back pain in as few as three days as confirmed by patient outcomes data.<\/p>\n

The \u201coutcomes data differentiates SOMA\u00ae 250 mg among the diverse treatment choices for patients with acute low back pain,” said\u00a0Steven M. Simon, MD, RPh, Clinical Assistant Professor at the\u00a0University of Kansas\u00a0School of Medicine and Biosciences.<\/p>\n

“Almost all acute low back pain is mechanical in origin and one in five patients with this condition suffers from significant limitations in activity. \u00a0Treatment of acute low back pain with SOMA\u00ae 250 mg has been shown to improve functionality, as measured by an internationally validated tool.\u201d<\/p>\n

Meda Pharmaceuticals, Inc. claims that SOMA\u00ae is the only skeletal muscle relaxant proven to significantly improve functionality in patients with acute low back pain as measured by the Roland-Morris Disability Questionnaire<\/a> (RMDQ), an internationally validated standard for measuring the degree of disability and functionality in patients with lower back pain.<\/p>\n

The Company\u2019s approach to assessing patient symptom progression during SOMA\u00ae treatment via the RMDQ is unique in that it is a form of outcomes-based healthcare. Outcomes-based health care has become an increasingly popular and comprehensive approach to healthcare with goals of providing high quality care and reducing treatment costs.<\/p>\n

“Overall, the greatest cost savings from a societal perspective may be obtained from interventions that promote early return to work and minimize lost productivity,” said\u00a0Al Moorad, MD, Medical Director, Integris Jim Thorpe Rehabilitation,\u00a0Oklahoma City. “This may be accomplished by appropriate drug utilization to allow patients to actively participate in rehabilitation therapy and return to daily activities.”<\/p>\n

Meda Pharmaceuticals\u2019 will present its findings this week at the 26th annual meeting of the American Academy of Pain Medicine in\u00a0San Antonio, TX.<\/p>\n

To learn more about SOMA\u00ae, you may visit\u00a0www.SOMA250.com<\/a>. The original press release pertaining to this article may be viewed at\u00a0www.prnewswire.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

By Johnathan Nieves Lower back pain is the fifth leading cause for doctor visits in the U.S. and over 85 percent of people suffer at least one bout of lower back pain in their lifetime. SOMA\u00ae, a new drug under development by, Meda Pharmaceuticals, Inc., a Somerset, N.J. based company, has been shown to improve … Continue reading New Drug Shown to Heal Back Pain in 3 Days<\/span><\/a><\/p>\n","protected":false},"author":265,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2075,2074],"tags":[2105,2102,2104],"class_list":["post-46","post","type-post","status-publish","format-standard","hentry","category-brain-and-body","category-treatment","tag-medical-advances","tag-pain-management","tag-pharmacology"],"_links":{"self":[{"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/posts\/46","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/users\/265"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/comments?post=46"}],"version-history":[{"count":0,"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/posts\/46\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/media?parent=46"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/categories?post=46"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.dickinson.edu\/sciencenews\/wp-json\/wp\/v2\/tags?post=46"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}